Brukinsa (zanubrutinib capsules and tablets) — Cigna
Primary Central Nervous System Lymphoma
Initial criteria
- Patient age ≥ 18 years
- Patient has tried at least one systemic regimen
- Medication used in combination with autologous stem cell reinfusion
Approval duration
1 year